Management of hematologic toxicity in patients with advanced or metastatic gastric cancer treated with docetaxel, cisplatin and fluorouracil (DCF): Results of monocentric experience

Turano Salvatore¹,², Biamonte Rosalbino¹, Conforti Serafino¹, Mastroianni Candida Maria¹, Manfredi Caterina¹, Palazzo Salvatore¹

¹U. O. C. Oncologia Medica S. O. “Mariano Santo” Azienda Ospedaliera Cosenza
²Ospedale Mariano Santo UOC Oncologia Medica (dir S. Palazzo) c/da Muoio Piccolo 87100 Cosenza, Italy

Email address: galactus76@yahoo.it (Turano S.)

To cite this article:

Abstract: Background: Gastric adenocarcinoma is the second most common cause of cancer death worldwide. There is no standard regimen of chemotherapy for metastatic disease, although the regimen of ECF is the most used regimen, with a median survival of 7-9 months. With new regimens of chemotherapy, such as DCF, the median survival has increased, despite a major toxicities and 1-2% of toxic death. Patients And Methods: This is a monocentric experience. In three years (2009-2012) we have treated 36 chemo-naïve patients with histological diagnosis of locally advanced or metastatic gastric cancer with a DCF regimen. All patients were treated with a prophylactic Peg-filgrastim injection at 6th day of therapy. Results: A total of 168 cycles were administered (median 5 per patient, range 3–8). Major responses were observed in 10 patients, with 2 complete (5,5%) and 8 partial remissions (22,2%); 16 additional pts showed disease stabilization (44,4%) and 10 progressed (27,9%). Median OS times were 12 months. Median TTP were 9,5 months. Toxicity was acceptable, worst per patient toxicities were neutropenia (grade 3-4 in 15%), feverish neutropenia (11,1%) diarrhoea (grade 2 in 25%, grade 3 in 25%, grade 4 in 18,8%), asthenia (grade 2 in 8%), neurotoxicity (grade 3 in 4%), anemia (grade 4 in 10%), four pts received blood transfusion. Conclusion: Time to response and ORR favor DCF over other schedule’s treatment according to literature. A trend towards increased myelosuppression and infectious complications was observed but the management of this and others side-effects is possible and not too difficult if pts is managed by an expert toxicities team. Infact we don’t have no-one toxic death.

Keywords: Gastric Cancer, DCF, Hematologic Toxicity

1. Introduction

Gastric cancer is one of the most frequent malignancies in Europe since the fifth cancer incidence for both the male and in female. Over the past decades, the epidemiology of gastric cancer has been profoundly modified by a significant decrease in incidence and mortality. The incidence and mortality are widely different in different regions of the world. In Europe there are about 192,000 new cases per year with an incidence 1.6 times higher in males. The annual incidence rates standardized by age show a greater incidence in Eastern Europe (34.1/100,000) and South (19.5/100,000) than Western Europe (7/100,000) and North (6.1 / 100,000)¹.

The precise number of cancer cases diagnosed each year in Italy is unknown because complete cancer registration has not yet been achieved in many regions.

Despite the presence of numerous epidemiological studies, the etiology of gastric cancer is not perfectly known. The gastric carcinogenesis is a multifactor process with progressive deterioration and involving environmental irritants, bacterial infections, changes in acid secretion, production of nitrite and N - nitrous compounds derived from food. The results of this cascade of events result in a gradual transition from normal epithelium to gastric cancer. There were many assumptions and interpretations have been relied on ethnicity, economic status, blood group and type of
nutrition, also were deemed responsible for pathological conditions such as achlorhydria defined predisposing or ipolioridria, pernicious anaemia, gastric polyposis, the atrophic gastritis, intestinal metaplasia gastric and chronic ulcer. A prognostic factor of great importance is represented by a previous Billroth II gastric resection type, for a possible mucolytic action of bile reflux and increased production of nitrosamines as a result of the presence of intestinal bacterial flora and the changes in pH.

In Italy gastric cancer is the 5th in order of cancer incidence with almost 17000 new cases per year (5th in men after lung, colorectal, bladder and prostate and 3rd in women after breast and colorectal). Although in Italy there is any decline in mortality, this seems to reflect the parallel decline in the incidence, well documented, even in our country, from the mid 70s.

Even today, in the Western world, over 60% of patients come to surgery in Stage III or IV (pT2 N2, T3 N1, T4 N0, T3 N2, T4 N1, T4 N2, M1), and also for patients undergoing curative surgery the 5-year survival does not exceed 15-30% and loco-regional recurrence (38-67%) and distance (25-52%) are divided almost equally responsible for this high mortality. Clearly, therefore demonstrates the importance of a therapeutic approach focuses on advanced or recurrent forms, in fact over the past 2 decades have been all over the world, numerous efforts by surgeons, radiation oncologists and physicians to achieve better results. Particularly in the field of chemotherapy for advanced or recurrent forms there has been the definitive proof that the modern chemotherapy schedules have an advantage over best supportive care and, almost certainly on other single agent approaches. However, no protocol, among those currently available, can be considered the 'gold standard', as many are equivalent in terms of ORR is PFS or OS because the results obtained so far in terms of OS (8-12 months) are still widely considered inadequate.

The possibility that, as yet, practically, before new therapies are made to finalize (eg angiogenesis inhibitors, vaccinations etc...), go through the optimization of the use of existing drugs (new modalities and timing of administration) and their associations (new combination therapies).

More recently highlighted the effectiveness of combination chemotherapy such as docetaxel and cisplatin (TC)\(^3\), Docetaxel, cisplatin and 5-fluorouracil (TCF)\(^4\).

In a recent randomized phase II combination DCF (docetaxel 85 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-Fluorouracil 300 mg/m2/die in IC 2 weeks every 3 weeks) achieved better results (which are still supported by a randomized phase III) compared to TC and ECF, reporting an overall response rate respectively of 55%, 42% and 46% and a median time to progression of 7.3, 4.3 and 5.0 months\(^5\).

Another randomized phase III study comparing the pattern DCF (docetaxel 75 mg/m2 days 1, cisplatin 75 mg/m2 days 1, 5-Fluorouracil 750 mg/m2/die in IC on days 1-5, every 3 weeks) combined with CF (cisplatin 100 mg/m2 days 1 and 5-Fluorouracil in 1000 mg/m2/die CI on days 1-5 every 4 weeks) showed a benefit of DCF regarding: median time to progression (5.6 vs 3.7 months), survival at 2 years (18% vs 9%) and overall response rate (37% vs 25%) with an acceptable toxicity profile for the association of three drugs\(^6,16\).

In view of these findings it is important to the management of toxicities' haematological (neutropenia and febrile neutropenia) and in the schedule are higher than DCF and CF, especially in elderly patients and those with comorbidities or performance status deteriorated\(^11\).

The introduction of growth factors in the early 90 has had and continues to have a profound impact on oncology practice. The numerous studies of these cytokines have enabled us to gather a lot of information about both their biological effects on both the indirect effects resulting from the reduction of neutropenia, anemia or thrombocytopenia\(^17,18\).

Several mAbs and kinase inhibitors, especially those targeting EGFR and VEGF/VEGFR, have already demonstrated promising activity in gastric cancer. Trastuzumab was the first targeted agent to be approved for the treatment of advanced gastric cancer in 2010. The Phase III TOGA trial reported an increase in overall survival for patients with human EGF receptor (HER)2-positive gastric cancer treated with chemotherapy and trastuzumab compared to chemotheraphy alone\(^33,34\). The failure of the AVAGAST trial\(^15\) was a setback for anti-angiogenic therapy for this disease. Ramucirumab\(^19\) is a monoclonal antibody that binds to VEGF-R2 and prevents its activation. The recent REGARD trial was a randomized phase III trial of ramucirumab vs. placebo for patients with advanced, pre-treated gastric cancer that met its primary endpoint of increased overall survival.

With specific reference to growth factors granulocyte (G-CSF) and granulocyte-macrophage (GM-CSF), the stock of knowledge continues to expand today: in terms of clinical and pathophysiological point of view, making this class of drugs among most 'versatile oncohaematology'\(^19,20\).

The growth factors granulocyte intervene directly on the natural history and prognosis of the disease and then use the G-CSF mean, in light of the results of 15 years of large clinical trials and several meta-analysis, allowing the patient a better prognosis and better quality of life\(^21,22\).

We wanted to assess the safety. The primary objective of this study is to assess the impact of pegfigastarin on neutropenia induced by combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer. The secondary objective of the current study was to examine the other side effects.

### 2. Patients and Methods

From January 2009 to September 2012 were enrolled at our center, OU Of Medical Oncology, Azienda Ospedaliera di Cosenza, 36 patients with histological diagnosis of locally advanced or metastatic gastric cancer. Inclusion criteria were represented by: gastric or gastroesophageal junction...
adenocarcinoma histologically documented, measurable metastatic and/or assessed according to WHO criteria, when present, or at least 1 local recurrence with lymph node measured, Age> 18 years, PS sec. ECOG 0-2, life expectancy> 3 months, adequate hematologic function (Hb ≥ 10 g / dl, neutrophils ≥ 1500, platelets ≥ 10.000 MMC), creatinine clearance ≥ 30 ml/min., Adequate liver function: bilirubin ≤ 1.25 x VNM (or ≤ 1.5 x VNM in the presence of liver metastases), SGOT and SGPT ≤ 1.5 x VNM (or ≤ 2.5 xVNM in the presence of liver metastases), normal cardiac function: ejection fraction ≥ 50% assessed echocardiography, patient compliance and geographic conditions that allow attachment to the follow-up.

Main exclusion criteria were as follows: prior palliative chemotherapy or prior treatment with taxanes; symptomatic peripheral neuropathy; known brain or leptomeningeal metastases; liver impairment with ALT and/or AST more than 1.5x the upper limit of normal associated with alkaline phosphatase more than 2.5x the upper limit of normal; and other serious medical condition that could impair participation in the study. Written informed consent was obtained from all patients.

Before starting treatment, patients underwent complete medical examination, evaluation of performance status (ECOG), measurement of metastatic lesions with ultrasound or CT scans where possible. All patients were treated with a regimen: docetaxel 75 mg/m2 in 1 hour infusion, CDPD 75 mg / m² IV 1 to 3 hours of infusion 1 g, 5-FU 750 mg / m2/die continuous infusion for 5 days (DCF) every three weeks until disease progression or onset of severe toxicity. All patients also received prophylactic treatment with PEG-filgrastim 6 mg on the sixth day of every cycles of therapy. The patients received an average relative dose intensity of =/> 75%. Less than 15% of patients experienced a dose delay, and < 10% of patients received a chemotherapy reduction Responses were assessed at the end of each cycle according to WHO criteria and toxicity every week according to NCI CTC. Patients who have completed at least one cycle of chemotherapy were considered evaluable for toxicity.

The follow-up was carried out over a year after the last cycle of chemotherapy, and was carried out with medical consultation and blood chemistry every 3 months, CT abdomen and chest X-ray every 6 months.

3. Results

Were administered a total of 168 treatment cycles with an average of 5 cycles per patient (range 3-8). Responses to therapy: complete response (CR) 2 (5.5%) partial response (PR) 8 (22.2%), stabilization disease (SD) 16 (44.4%), progression disease (PD) 10 (27.9%). The median overall survival was 12 months while the median time to progression was of 9.5 months. The toxicity has been accepted. In particular, regarding hematological toxicity, we observed: grade 3-4 neutropenia in (15%), febrile neutropenia (11.1%), grade 4 anemia (10%). Toxicities' non-haematological were: diarrhea grade 2 (25%) grade 3 (25%) grade 4 (18.8%), grade 2 asthenia (8%) neurotoxicity 'grade 3-4 (4%). Only 4 patients received blood transfusion.

4. Discussion

The V325 trial is the largest randomized, controlled trial that formally and systematically assessed QoL in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma23.

In summary, the V325 randomized phase III trial results in a significantly better preservation of QoL for patients treated with DCF than patients treated with CF. In this study, better preservation of QoL occurred as a result of a significantly higher level of efficacy imparted by the addition of docetaxel to CF compared with CF alone despite a higher incidence of some toxicities as a result of the addition of docetaxel to CF. Clearly, the quantity and quality of life are important outcomes and, ideally, treatment should enhance both. The research on QoL provides a qualitative and quantitative background to integrate these elements into the decision-making process. The QoL results of the V325 study consistently favored DCF over CF, supporting the benefit of DCF in patients with advanced gastric or gastroesophageal junction adenocarcinoma24.

The hematologic toxicity represented and represent a daily problem in clinical practice for the specialist oncologist both in the elderly patient and young patient management.

The introduction of granulocyte growth factors as part of the treatment plan has allowed us to intervene directly on the prognosis and natural history of disease.

A number of initiatives are under way to begin to measure and improve the quality of cancer care, including the American Society of Clinical Oncology’s (ASCO’s) Quality Oncology Practice Initiative,26 the National Initiative for Cancer Care Quality (NICCQ),27 and the Oncology Demonstration Project sponsored by the Centers for Medicare and Medicaid Services.28 In addition to improving the quality of care associated with the diagnosis, staging, and cancer-related therapy, an equally important priority is to ensure that patients receive appropriate supportive care to manage both disease symptoms and treatment-related toxicity.29,30,31

In our study, we want to evaluate the impact of pegfilgrastim on the neutropenia chemotherapy-related. Our second goal is to highlight how the toxicities due to DCF
thrice-weekly schedule for the treatment of gastric cancer can be reduced and controlled if the patient is followed by a team experienced in the toxicity management.

36 patients with locally advanced or metastatic gastric cancer were enrolled and treated with a schedule Docetaxel 75 mg/m2, CDDP 75 mg/m2, 5FU 750 mg/m2 every three weeks.

The responses, when compared with the data reported for other schedules as reported in the literature, were in favor of DCF in terms of both TTR and ORR, both for overall survival and time to progression.

The prophylactic treatment with PEG-filgrastim administered on the sixth day of therapy in all patients, has allowed a major reduction and better management of hematological toxicities when compared with data of TAX 325 study.\textsuperscript{16} In this study there was no requirement to use growth factors granulocyte toxicity and there was hematological neutropenia grade 3-4 (82%), febrile neutropenia (29%), grade 3-4 anemia (18%).

In our experience, we have associated with chemotherapy treatment a granulocyte growth factor using PEG-filgrastim on the sixth day of therapy. This enabled us to significantly reduce the hematologic toxicity of allowing the patient a better prognosis and a better quality of life (QoL).

Therefore, more than fifteen years after the introduction of growth factors in oncology, there is no doubt that they are an essential for achieving various objectives garrison including QoL. The limit of our study consists in amance of a control group.

5. Conclusions

It’s important to stress that the results were obtained in a group of patients more realistic (over seventy patients with diseases associated) and less than that explored in selected studies, and for that reason has been the subject of criticism in the months following the publication.

These findings underscore the need for observational research to evaluate the effectiveness of therapy in heterogeneous patient populations treated in our oncology unit. While all new U.S. pharmaceutical therapies undergo rigorous evaluation to demonstrate their safety and efficacy during the FDA approval process, variations in actual use and the diversity of patient populations may have a small but measurable impact on the effectiveness of medications.\textsuperscript{32}

It is also important to stress that in our study there were no deaths from toxic effects compared with an incidence of 3-7% in the literature, despite the characteristics of the patients expressed above. This is primarily due to a good and timely management of expectations and toxicity prevention performed with peg-filgrastim.

We conclude that the use of prophylactic growth factor support was associated with a high proportion of chemotherapy cycles that were delivered on schedule and at full dose.

Our monocentric experience confirms that the DCF scheme in locally advanced or metastatic gastric carcinoma is a scheme with an acceptable toxicity even in not highly selected patients. Of course, the results of our study will be confirmed in randomized phase III multicenter studies.

References


